Trial intelligence / Profile preview

My Pathway

NCT02091141Phase 2Completed

Sponsor: Genentech
Start: Apr 2014
Primary completion: May 2023
Modality: Fragment-Derived Small Molecules, Antibody Conjugates, Monoclonal Antibodies
Countries: 1

Overview

Phase 2, open-label trial of trastuzumab, pertuzumab, atezolizumab, vemurafenib, cobimetinib and 3 more in solid tumor (7 arms), sponsored by Genentech. Primary endpoints: Overall Response Rate at 72.1 months and Overall Response Rate (Independent Review Committee) at 68.9 months. Started Apr 2014; status: completed.

Drugs

trastuzumabpertuzumabatezolizumabvemurafenibcobimetinib

Conditions

solid tumor

Beyond the preview

Go deeper on NCT02091141.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02091141.